Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes, Catherine C. Smith, Mark R. Litzow, Maria R. Baer, David F. Claxton, Harry P. Erba, Stan Gill, Stuart L. Goldberg,

The Lancet Oncology · 2017 · 488 citations · 37 references

DOIFull text

Open access

Concepts

References

37